Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2013 Elsevier Ltd. Cerebrospinal fluid, imaging and blood based biomar-kers can provide critical information for dose selection, patient enrichment and supplementary evidence of disease modification in current clinical trials testing experimental therapeutics for Alzheimer's disease (AD). The current treatise provides examples of biomarker strategies utilized in AD clinical trial practice and highlights recent advances towards the identifica-tion of non-invasive approaches for enrichment and diagnosis.

Original publication

DOI

10.1016/j.ddstr.2013.09.002

Type

Journal article

Journal

Drug Discovery Today: Therapeutic Strategies

Publication Date

01/01/2013

Volume

10

Pages

e55 - e62